Abstract
Background: We aimed to determine the similarities and differences in the roles of genic and regulatory copy number variations (CNVs) in bipolar disorder (BD), schizophrenia (SCZ), and autism spectrum disorder (ASD). Methods: Based on high-resolution CNV data from 8708 Japanese samples, we performed to our knowledge the largest cross-disorder analysis of genic and regulatory CNVs in BD, SCZ, and ASD. Results: In genic CNVs, we found an increased burden of smaller (<100 kb) exonic deletions in BD, which contrasted with the highest burden of larger (>500 kb) exonic CNVs in SCZ/ASD. Pathogenic CNVs linked to neurodevelopmental disorders were significantly associated with the risk for each disorder, but BD and SCZ/ASD differed in terms of the effect size (smaller in BD) and subtype distribution of CNVs linked to neurodevelopmental disorders. We identified 3 synaptic genes (DLG2, PCDH15, and ASTN2) as risk factors for BD. Whereas gene set analysis showed that BD-associated pathways were restricted to chromatin biology, SCZ and ASD involved more extensive and similar pathways. Nevertheless, a correlation analysis of gene set results indicated weak but significant pathway similarities between BD and SCZ or ASD (r = 0.25–0.31). In SCZ and ASD, but not BD, CNVs were significantly enriched in enhancers and promoters in brain tissue. Conclusions: BD and SCZ/ASD differ in terms of CNV burden, characteristics of CNVs linked to neurodevelopmental disorders, and regulatory CNVs. On the other hand, they have shared molecular mechanisms, including chromatin biology. The BD risk genes identified here could provide insight into the pathogenesis of BD.
Original language | English |
---|---|
Pages (from-to) | 362-374 |
Number of pages | 13 |
Journal | Biological Psychiatry |
Volume | 92 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2022 Sept 1 |
Keywords
- Autism spectrum disorder
- Bipolar disorder
- Chromatin biology
- Copy number variation
- Cross-disorder analysis
- Schizophrenia
ASJC Scopus subject areas
- Biological Psychiatry
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder. / Kushima, Itaru; Nakatochi, Masahiro; Aleksic, Branko et al.
In: Biological Psychiatry, Vol. 92, No. 5, 01.09.2022, p. 362-374.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder
AU - Kushima, Itaru
AU - Nakatochi, Masahiro
AU - Aleksic, Branko
AU - Okada, Takashi
AU - Kimura, Hiroki
AU - Kato, Hidekazu
AU - Morikawa, Mako
AU - Inada, Toshiya
AU - Ishizuka, Kanako
AU - Torii, Youta
AU - Nakamura, Yukako
AU - Tanaka, Satoshi
AU - Imaeda, Miho
AU - Takahashi, Nagahide
AU - Yamamoto, Maeri
AU - Iwamoto, Kunihiro
AU - Nawa, Yoshihiro
AU - Ogawa, Nanayo
AU - Iritani, Shuji
AU - Hayashi, Yu
AU - Lo, Tzuyao
AU - Otgonbayar, Gantsooj
AU - Furuta, Sho
AU - Iwata, Nakao
AU - Ikeda, Masashi
AU - Saito, Takeo
AU - Ninomiya, Kohei
AU - Okochi, Tomo
AU - Hashimoto, Ryota
AU - Yamamori, Hidenaga
AU - Yasuda, Yuka
AU - Fujimoto, Michiko
AU - Miura, Kenichiro
AU - Itokawa, Masanari
AU - Arai, Makoto
AU - Miyashita, Mitsuhiro
AU - Toriumi, Kazuya
AU - Ohi, Kazutaka
AU - Shioiri, Toshiki
AU - Kitaichi, Kiyoyuki
AU - Someya, Toshiyuki
AU - Watanabe, Yuichiro
AU - Egawa, Jun
AU - Takahashi, Tsutomu
AU - Suzuki, Michio
AU - Sasaki, Tsukasa
AU - Tochigi, Mamoru
AU - Nishimura, Fumichika
AU - Yamasue, Hidenori
AU - Kuwabara, Hitoshi
AU - Wakuda, Tomoyasu
AU - Kato, Takahiro A.
AU - Kanba, Shigenobu
AU - Horikawa, Hideki
AU - Usami, Masahide
AU - Kodaira, Masaki
AU - Watanabe, Kyota
AU - Yoshikawa, Takeo
AU - Toyota, Tomoko
AU - Yokoyama, Shigeru
AU - Munesue, Toshio
AU - Kimura, Ryo
AU - Funabiki, Yasuko
AU - Kosaka, Hirotaka
AU - Jung, Minyoung
AU - Kasai, Kiyoto
AU - Ikegame, Tempei
AU - Jinde, Seiichiro
AU - Numata, Shusuke
AU - Kinoshita, Makoto
AU - Kato, Tadafumi
AU - Kakiuchi, Chihiro
AU - Yamakawa, Kazuhiro
AU - Suzuki, Toshimitsu
AU - Hashimoto, Naoki
AU - Ishikawa, Shuhei
AU - Yamagata, Bun
AU - Nio, Shintaro
AU - Murai, Toshiya
AU - Son, Shuraku
AU - Kunii, Yasuto
AU - Yabe, Hirooki
AU - Inagaki, Masumi
AU - Goto, Yu ichi
AU - Okumura, Yuto
AU - Ito, Tomoya
AU - Arioka, Yuko
AU - Mori, Daisuke
AU - Ozaki, Norio
N1 - Funding Information: This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and the Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development (Grant Nos. JP20dm0107087 [to NOz], JP21wm0425007 [to NOz], JP21dm0207075 [to NOz], JP21ak0101113 [to NOz], JP20dk0307075 [to NOz, TAK], JP20dk0307081 [to NOz], JP21dk0307103 [to NOz, RH], JP21km0405216 [to MN, IK], JP21ek0109411 [to IK], JP20dm0107160 [to TOka], JP18dm0107088 [to MIt], JP19dm0107088 [to MIt], JP20dm0107088 [to MIt], JP20dm0107092 [to KY], JP21dm0207069 [to MY], JP21wm0425019 [to YK], JP21dm0207074 [to YK], JP19lk0201071 [to HYamas], JP20lk0201116 to [HYamas], JP16dm0107134 [to HYamas], JP16dk0307029 [to MS], JP20dm0107083 [to TY], JP20km0405208 [to MIk, TK], JP20dm0207074 [to TK], JP20dm0107097 [to NI, MIk], JP21wm0425008 [to NI, MIk], JP21tm0424220 [to MIk], JP20km0405201 [to NI, MIk], and JP21wm0525024 [to MIk]), Japan Society for the Promotion of Science (KAKENHI Grant Nos. JP23110506 [to NOz], JP23700443 [to NOz], JP25110715 [to NOz], JP25460284 [to NOz], JP17H05090 [to IK], JP15K19720 [to IK], JP18H04040 [to NOz], JP21K07543 [to IK], JP20K20602 [to NOz], JP21H00194 [to IK], JP21H04815 [to NOz], JP17K10295 [to MY], JP21K07498 [to MY], JP19K17061 [to SS], JP18K07550 [to TTa], JP16H05380 [to MA], JP17H05930 [to MA], JP19H04887 [to MA], JP20H03608 [to MA], JP21H00180 [to YK], JP19K08053 [to YK], JP20H03598 [to MS], JP18H05435 [to TK], JP18H05428 [to TK], JP19K08081 [to KO], JP17H04251 [to MIk], JP16H06277 [to MN], and JP21H02854 [to MIk]), Private University Research Branding Project from MEXT [to NI], Collaborative Research Project of the Brain Research Institute, Niigata University (Grant No. 201917) [to YK], National Center of Neurology and Psychiatry Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders [to RH], Uehara Memorial Foundation [to MA, IK], SENSHIN Medical Research Foundation [to NI, MIk, IK, MA], and Sumitomo Foundation [to MA]. We thank all patients and their families for participating in this study. We also thank Mami Yoshida, Kiyori Monta, Hiromi Noma, and Yukari Mitsui for their technical assistance. IK has received research/grant support from AMED, MEXT/JSPS, Novartis Pharma, GlaxoSmithKline, Takeda Pharmaceutical Co. Ltd. Hori Sciences and Arts Foundation, Uehara Memorial Foundation, and the SENSHIN Medical Research Foundation. SIs has received personal fees from Janssen Pharmaceutical, Sumitomo Dainippon Pharma Co. Ltd. Eisai Co. Ltd. and Meiji Seika Pharma and research/grant support from Eli Lilly. SNu has received research grants, rewards for lectures, and donations from Astellas Pharma Inc. Eisai Co. Ltd. Otsuka Pharmaceutical Co. Ltd. Sumitomo Dainippon Pharma Co. Ltd. Eli Lilly Japan K.K. Novartis Pharma K.K. Pfizer Inc. Meiji Seika Pharma Co. Ltd. Mochida Pharmaceutical Co. Ltd. Janssen Pharmaceutical K.K. Kyowa Pharmaceutical Industry Co. Ltd. Takeda Pharmaceutical Co. Ltd. and Yoshitomiyakuhin Co. MIt has been awarded patents regarding the therapeutic use of pyridoxamine for schizophrenia. NOz has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon Pharma Co. Ltd. Eisai Co. Ltd. Otsuka, KAITEKI, Mitsubishi Tanabe, Shionogi, Eli Lilly, Mochida, DAIICHI SANKYO, Nihon Medi-Physics, Takeda, Meiji Seika Pharma, EA Pharma, Pfizer, MSD, Lundbeck Japan, and Taisho Pharma Co. outside the submitted work. NI has received research support or speakers’ honoraria from, or has served as a consultant to, Jansen, GlaxoSmithKline, Eli Lilly, Otsuka, Shionogi, Sumitomo Dainippon Pharma Co. Ltd. Tanabe Mitsubishi, and Daiichi-Sankyo. TK has received grants and personal fees from AMED and MEXT/JSPS during the conduct of the study and personal fees from Kyowa Hakko Kirin Co. Ltd. Eli Lilly Japan K.K. GlaxoSmithKline, Taisho Pharma Co. Meiji Seika Pharma Co. Ltd. Pfizer Japan Inc. Mochida Pharmaceutical Co. Ltd. Janssen Pharmaceutical K.K. Janssen Asia Pacific, Yoshitomiyakuhin Co. Astellas Pharma Inc. Nippon Boehringer Ingelheim Co. Ltd. MSD K.K. Kyowa Pharmaceutical Industry Co. Ltd. Taisho Pharmaceutical Co. Ltd. and Taisho Toyama Pharmaceutical Co. Ltd.; grants and personal fees from Otsuka Pharmaceutical Co. Ltd. Sumitomo Dainippon Pharma Co. Ltd. Shionogi & Co. Ltd. Takeda Pharmaceutical Co. Ltd. Eisai Co. Ltd. and Mitsubishi Tanabe Pharma Corp.; and grants from Teijin Pharma outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and the Ministry of Health, Labour and Welfare of Japan , Japan Agency for Medical Research and Development (Grant Nos. JP20dm0107087 [to NOz] , JP21wm0425007 [to NOz] , JP21dm0207075 [to NOz] , JP21ak0101113 [to NOz] , JP20dk0307075 [to NOz, TAK] , JP20dk0307081 [to NOz] , JP21dk0307103 [to NOz, RH] , JP21km0405216 [to MN, IK] , JP21ek0109411 [to IK] , JP20dm0107160 [to TOka] , JP18dm0107088 [to MIt] , JP19dm0107088 [to MIt] , JP20dm0107088 [to MIt] , JP20dm0107092 [to KY] , JP21dm0207069 [to MY] , JP21wm0425019 [to YK] , JP21dm0207074 [to YK] , JP19lk0201071 [to HYamas] , JP20lk0201116 to [HYamas] , JP16dm0107134 [to HYamas] , JP16dk0307029 [to MS] , JP20dm0107083 [to TY] , JP20km0405208 [to MIk, TK] , JP20dm0207074 [to TK] , JP20dm0107097 [to NI, MIk] , JP21wm0425008 [to NI, MIk] , JP21tm0424220 [to MIk] , JP20km0405201 [to NI, MIk], and JP21wm0525024 [to MIk] ), Japan Society for the Promotion of Science (KAKENHI Grant Nos. JP23110506 [to NOz] , JP23700443 [to NOz] , JP25110715 [to NOz] , JP25460284 [to NOz] , JP17H05090 [to IK] , JP15K19720 [to IK] , JP18H04040 [to NOz] , JP21K07543 [to IK] , JP20K20602 [to NOz] , JP21H00194 [to IK] , JP21H04815 [to NOz] , JP17K10295 [to MY] , JP21K07498 [to MY] , JP19K17061 [to SS] , JP18K07550 [to TTa] , JP16H05380 [to MA] , JP17H05930 [to MA] , JP19H04887 [to MA] , JP20H03608 [to MA] , JP21H00180 [to YK] , JP19K08053 [to YK] , JP20H03598 [to MS] , JP18H05435 [to TK] , JP18H05428 [to TK] , JP19K08081 [to KO] , JP17H04251 [to MIk] , JP16H06277 [to MN] , and JP21H02854 [to MIk] ), Private University Research Branding Project from MEXT [to NI], Collaborative Research Project of the Brain Research Institute, Niigata University (Grant No. 201917) [to YK], National Center of Neurology and Psychiatry Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders [to RH], Uehara Memorial Foundation [to MA, IK], SENSHIN Medical Research Foundation [to NI, MIk, IK, MA], and Sumitomo Foundation [to MA]. Publisher Copyright: © 2022 Society of Biological Psychiatry
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: We aimed to determine the similarities and differences in the roles of genic and regulatory copy number variations (CNVs) in bipolar disorder (BD), schizophrenia (SCZ), and autism spectrum disorder (ASD). Methods: Based on high-resolution CNV data from 8708 Japanese samples, we performed to our knowledge the largest cross-disorder analysis of genic and regulatory CNVs in BD, SCZ, and ASD. Results: In genic CNVs, we found an increased burden of smaller (<100 kb) exonic deletions in BD, which contrasted with the highest burden of larger (>500 kb) exonic CNVs in SCZ/ASD. Pathogenic CNVs linked to neurodevelopmental disorders were significantly associated with the risk for each disorder, but BD and SCZ/ASD differed in terms of the effect size (smaller in BD) and subtype distribution of CNVs linked to neurodevelopmental disorders. We identified 3 synaptic genes (DLG2, PCDH15, and ASTN2) as risk factors for BD. Whereas gene set analysis showed that BD-associated pathways were restricted to chromatin biology, SCZ and ASD involved more extensive and similar pathways. Nevertheless, a correlation analysis of gene set results indicated weak but significant pathway similarities between BD and SCZ or ASD (r = 0.25–0.31). In SCZ and ASD, but not BD, CNVs were significantly enriched in enhancers and promoters in brain tissue. Conclusions: BD and SCZ/ASD differ in terms of CNV burden, characteristics of CNVs linked to neurodevelopmental disorders, and regulatory CNVs. On the other hand, they have shared molecular mechanisms, including chromatin biology. The BD risk genes identified here could provide insight into the pathogenesis of BD.
AB - Background: We aimed to determine the similarities and differences in the roles of genic and regulatory copy number variations (CNVs) in bipolar disorder (BD), schizophrenia (SCZ), and autism spectrum disorder (ASD). Methods: Based on high-resolution CNV data from 8708 Japanese samples, we performed to our knowledge the largest cross-disorder analysis of genic and regulatory CNVs in BD, SCZ, and ASD. Results: In genic CNVs, we found an increased burden of smaller (<100 kb) exonic deletions in BD, which contrasted with the highest burden of larger (>500 kb) exonic CNVs in SCZ/ASD. Pathogenic CNVs linked to neurodevelopmental disorders were significantly associated with the risk for each disorder, but BD and SCZ/ASD differed in terms of the effect size (smaller in BD) and subtype distribution of CNVs linked to neurodevelopmental disorders. We identified 3 synaptic genes (DLG2, PCDH15, and ASTN2) as risk factors for BD. Whereas gene set analysis showed that BD-associated pathways were restricted to chromatin biology, SCZ and ASD involved more extensive and similar pathways. Nevertheless, a correlation analysis of gene set results indicated weak but significant pathway similarities between BD and SCZ or ASD (r = 0.25–0.31). In SCZ and ASD, but not BD, CNVs were significantly enriched in enhancers and promoters in brain tissue. Conclusions: BD and SCZ/ASD differ in terms of CNV burden, characteristics of CNVs linked to neurodevelopmental disorders, and regulatory CNVs. On the other hand, they have shared molecular mechanisms, including chromatin biology. The BD risk genes identified here could provide insight into the pathogenesis of BD.
KW - Autism spectrum disorder
KW - Bipolar disorder
KW - Chromatin biology
KW - Copy number variation
KW - Cross-disorder analysis
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85132578719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132578719&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2022.04.003
DO - 10.1016/j.biopsych.2022.04.003
M3 - Article
C2 - 35667888
AN - SCOPUS:85132578719
SN - 0006-3223
VL - 92
SP - 362
EP - 374
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 5
ER -